Neuberg Diagnostics has forged a strategic joint venture with Sehgal Path Lab, focusing on enhancing the Haemato-Oncology segment. As part of this collaboration, Sehgal Path Lab will soon undergo a rebranding, becoming Neuberg Sehgal Path Lab. Dr. Kunal Sehgal, a highly regarded haematopathologist, will retain his role as the Managing Director and Chief Pathologist of the joint venture.
Dr. GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, expressed enthusiasm about partnering with Dr. Kunal Sehgal, emphasizing Neuberg’s commitment to delivering exceptional diagnostic services. He highlighted the strategic consolidation in Maharashtra, with Neuberg’s presence in Mumbai and Pune, reinforcing the company’s leadership position in various states and laying the groundwork for further growth and innovation in healthcare.
Dr. Kunal Sehgal, in his capacity as Managing Director and Chief Pathologist of Neuberg Sehgal Path Lab, expressed delight in partnering with Neuberg Diagnostics. He emphasized leveraging Neuberg’s advanced technologies and Sehgal Path Lab’s trusted reputation to offer patients comprehensive diagnostic services, including advanced genetic and oncology testing. Dr. Sehgal also outlined plans to expand research, education initiatives, training programs, and collaborations with educational and research institutions to advance the field of Haematopathology in India.
The joint venture between Neuberg Diagnostics and Sehgal Path Lab aims to provide patients with unparalleled diagnostic services while advancing research and education in the field of Haematopathology, underlining a commitment to innovation and excellence in healthcare.